Prolevi Bio

Prolevi’s long term vision is to treat metabolic disorders deploying our platform patent pending technology. They personalize the formulations in synergy with circadian rhythm.

Prolevi Bio will initially focus on bringing treatment to hypothyroid patients. 90% of patients, largely women remain dissatisfied and ignored with the current treatment. They suffer from broad symptoms despite normal hormone blood levels with existing therapy. This is due to lack of reliable tests, non-effective treatment and unstandardized worldwide screening (that should include fT3, fT4, rT3, T3, T4, and TSH). Prolevi’s solution ensures personalized therapy based on patient’s baseline characteristics.